Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit: 2017-2024

Historic Gross Profit for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to $663.6 million.

  • Apellis Pharmaceuticals' Gross Profit rose 165.84% to $434.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 46.02%. This contributed to the annual value of $663.6 million for FY2024, which is 96.30% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Gross Profit of $663.6 million as of FY2024, which was up 96.30% from $338.1 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Gross Profit ranged from a high of $663.6 million in FY2024 and a low of $66.4 million during FY2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Gross Profit value was $338.1 million (recorded in 2023), while the average stood at $357.2 million.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 4,842.59% in 2020, then slumped by 73.52% in 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' Gross Profit (Yearly) stood at $250.6 million in 2020, then plummeted by 73.52% to $66.4 million in 2021, then climbed by 5.16% to $69.8 million in 2022, then soared by 384.45% to $338.1 million in 2023, then spiked by 96.30% to $663.6 million in 2024.